Published in N Engl J Med on January 04, 2007
Drugs and valvular heart disease. N Engl J Med (2007) 3.41
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry. Alzheimers Res Ther (2014) 1.57
Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. J Neurol (2007) 1.53
Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary (2011) 1.50
Diagnosis and management of restless legs syndrome in children. Sleep Med Rev (2009) 1.49
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol (2009) 1.44
The Treatment of Cushing's Disease. Endocr Rev (2015) 1.35
Management of Cushing disease. Nat Rev Endocrinol (2011) 1.26
Acromegaly. Endocrinol Metab Clin North Am (2008) 1.23
Validation of suicide and self-harm records in the Clinical Practice Research Datalink. Br J Clin Pharmacol (2013) 1.22
Sleep and aging: 2. Management of sleep disorders in older people. CMAJ (2007) 1.11
Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care (2008) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Serotonin receptors and heart valve disease--it was meant 2B. Pharmacol Ther (2011) 0.99
Medical management of Cushing's disease: what is the future? Pituitary (2012) 0.99
Benfluorex and unexplained valvular heart disease: a case-control study. PLoS One (2010) 0.97
Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol (2009) 0.97
Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology (2010) 0.89
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord (2010) 0.88
Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab (2011) 0.87
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med (2008) 0.87
Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J Am Soc Echocardiogr (2009) 0.85
Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm (Vienna) (2009) 0.84
A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab (2013) 0.84
Medical treatment of Cushing's disease: Overview and recent findings. Int J Gen Med (2009) 0.84
Management of acromegaly in Latin America: expert panel recommendations. Pituitary (2010) 0.83
Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism. ACS Med Chem Lett (2013) 0.83
Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer. Rambam Maimonides Med J (2012) 0.82
Dopamine receptors and Parkinson's disease. Int J Med Chem (2011) 0.81
Inflammatory regulation of valvular remodeling: the good(?), the bad, and the ugly. Int J Inflam (2011) 0.81
Pathological gambling and dopamine agonists: A phenotype? Neuropsychiatr Dis Treat (2007) 0.80
Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med (2014) 0.80
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. Eur J Clin Pharmacol (2011) 0.80
Does Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study. Iran J Pharm Res (2015) 0.79
Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy. Drug Alcohol Depend (2012) 0.79
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. J Neural Transm (Vienna) (2008) 0.79
Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials. J Clin Med Res (2016) 0.78
Parkinson's disease between internal medicine and neurology. J Neural Transm (Vienna) (2015) 0.77
Medical management of functioning pituitary adenoma: an update. Neurol Med Chir (Tokyo) (2014) 0.77
Pramipexole use and the risk of pneumonia. BMC Neurol (2012) 0.77
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics (2008) 0.77
Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res (2014) 0.77
Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation. F1000Res (2014) 0.77
Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database. Br J Clin Pharmacol (2012) 0.77
Restless legs syndrome: differential diagnosis and management with rotigotine. Neuropsychiatr Dis Treat (2009) 0.77
Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease. Curr Top Med Chem (2013) 0.76
New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy. J Neurooncol (2013) 0.76
Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications. J Neurol (2008) 0.76
Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol Metab (Seoul) (2014) 0.76
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.76
Cardiovascular effects of noncardiovascular drugs. Circulation (2009) 0.76
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.75
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.75
Dopamine agonists and the risk of valvular heart disease. Nat Clin Pract Neurol (2007) 0.75
Acute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro. Cardiovasc Pathol (2016) 0.75
Review of Presentation, Diagnosis and Management of Pituitary Tumours in Pregnancy. Obstet Med (2013) 0.75
Pergolide and cabergoline were associated with increased risk for newly diagnosed cardiac valve regurgitation. ACP J Club (2007) 0.75
Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood. US Endocrinol (2009) 0.75
Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders. J Cent Nerv Syst Dis (2011) 0.75
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. Yale J Biol Med (2016) 0.75
Cabergoline-induced tricuspid regurgitation: Case report and review of literature. Indian J Endocrinol Metab (2011) 0.75
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.75
Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Osteoporos Int (2015) 0.75
Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. Int J Pediatr Endocrinol (2015) 0.75
Pharmacotherapy: Valvulopathy in patients treated for hyperprolactinemia? Nat Rev Endocrinol (2010) 0.75
Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia. Drugs Real World Outcomes (2015) 0.75
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.75
Adverse drug reaction suggested by a clinical vignette. Clin Interv Aging (2011) 0.75
Best candidates for dopamine agonist withdrawal in patients with prolactinomas. Pituitary (2017) 0.75
Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia. Front Pharmacol (2017) 0.75
Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. J Neural Transm (Vienna) (2014) 0.75
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA (2005) 6.87
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med (2015) 6.68
Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol (2013) 5.28
Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med (2007) 5.14
Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med (2007) 3.94
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ (2012) 3.82
Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry (2009) 3.33
Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ (2006) 3.18
Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA (2013) 3.16
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ (2010) 3.09
Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology (2010) 3.08
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther (2008) 2.87
Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology (2008) 2.87
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest (2012) 2.65
ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst (2002) 2.64
The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol (2008) 2.60
Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol (2002) 2.58
Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49
Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ (2010) 2.40
Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation (2006) 2.34
Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis (2006) 2.29
Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat (2003) 2.24
Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages. Nat Clin Pract Rheumatol (2007) 2.18
Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis (2012) 2.17
Atrial fibrillation-induced cardiac troponin I release. Int J Cardiol (2013) 2.16
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum (2007) 2.16
The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J (2003) 2.10
Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. Infection (2015) 2.06
Interaction of serotonin reuptake inhibitors with tamoxifen. BMJ (2010) 2.06
Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ (2007) 2.02
Cardiovascular morbidity and mortality in COPD. Chest (2005) 2.01
Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol (2003) 1.98
Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs. Pharmacoepidemiol Drug Saf (2007) 1.98
Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med (2007) 1.96
Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J (2008) 1.94
Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ (2008) 1.91
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
The nested case-control study in cardiology. Am Heart J (2003) 1.84
Gender differences in survival following hospitalisation for COPD. Thorax (2010) 1.73
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J (2005) 1.71
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol (2007) 1.68
Cardiac autonomic dysfunction in Brugada syndrome. Circulation (2002) 1.68
The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes (2005) 1.67
The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J (2012) 1.67
Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol (2010) 1.66
Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail (2008) 1.64
Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace (2013) 1.63
"Largest amplitude ablation" is the optimal approach for typical atrial flutter ablation: a subanalysis from the AURUM 8 study. J Cardiovasc Electrophysiol (2012) 1.56
Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study. Europace (2010) 1.54
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost (2013) 1.53
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm (2005) 1.50
Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging (2012) 1.49
Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol (2006) 1.49
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48
Molecular insights into arrhythmogenic right ventricular cardiomyopathy caused by plakophilin-2 missense mutations. Circ Cardiovasc Genet (2012) 1.48
Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up. Europace (2011) 1.47
Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens (2014) 1.46
Use of lithium and the risk of injurious motor vehicle crash in elderly adults: case-control study nested within a cohort. BMJ (2004) 1.44
The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Ann Allergy Asthma Immunol (2004) 1.44
Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis. Int J Cardiol (2011) 1.44
In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem (2011) 1.43
Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. J Cardiovasc Electrophysiol (2004) 1.43
Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis (2012) 1.43
The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care (2012) 1.42
Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest (2012) 1.42
The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes (2005) 1.40
Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev (2010) 1.39
Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther (2002) 1.39
Antibiotics in primary prevention of stroke in the elderly. Stroke (2003) 1.39
Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. Cardiovasc Res (2003) 1.39
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke (2006) 1.38
Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol (2011) 1.37
Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A (2002) 1.37
Point: were industry-sponsored roflumilast trials appropriate? Yes. Chest (2014) 1.36
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ (2010) 1.32
MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain (2004) 1.31
Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ (2014) 1.27
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol (2012) 1.26
The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol (2008) 1.23
Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med (2013) 1.22
The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res (2008) 1.21
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Intern Med (2016) 1.21
Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf (2009) 1.19
Mortality after infection with methicillin-resistant Staphylococcus aureus (MRSA) diagnosed in the community. BMC Med (2008) 1.18
Steerable versus nonsteerable sheath technology in atrial fibrillation ablation: a prospective, randomized study. Circ Arrhythm Electrophysiol (2011) 1.16
Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res (2005) 1.15
Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. Basic Res Cardiol (2003) 1.15
Prescribing of potentially inappropriate medications for the elderly: an analysis based on the PRISCUS list. Dtsch Arztebl Int (2012) 1.14